182 related articles for article (PubMed ID: 21602899)
1. Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma.
Chen AI; Negrin RS; McMillan A; Shizuru JA; Johnston LJ; Lowsky R; Miklos DB; Arai S; Weng WK; Laport GG; Stockerl-Goldstein K
Bone Marrow Transplant; 2012 Apr; 47(4):516-21. PubMed ID: 21602899
[TBL] [Abstract][Full Text] [Related]
2. Autologous stem cell transplantation for follicular lymphoma: no benefit for early transplant?
Seyfarth B; Kuse R; Sonnen R; Glass B; Schmitz N; Dreger P
Ann Hematol; 2001 Jul; 80(7):398-405. PubMed ID: 11529465
[TBL] [Abstract][Full Text] [Related]
3. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
[TBL] [Abstract][Full Text] [Related]
4. Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation.
Comenzo RL; Hassoun H; Kewalramani T; Klimek V; Dhodapkar M; Reich L; Teruya-Feldstein J; Fleisher M; Filippa D; Nimer SD
Leukemia; 2006 Feb; 20(2):345-9. PubMed ID: 16319952
[TBL] [Abstract][Full Text] [Related]
5. High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial.
Vesole DH; Crowley JJ; Catchatourian R; Stiff PJ; Johnson DB; Cromer J; Salmon SE; Barlogie B
J Clin Oncol; 1999 Jul; 17(7):2173-9. PubMed ID: 10561273
[TBL] [Abstract][Full Text] [Related]
6. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial.
Moreau P; Facon T; Attal M; Hulin C; Michallet M; Maloisel F; Sotto JJ; Guilhot F; Marit G; Doyen C; Jaubert J; Fuzibet JG; François S; Benboubker L; Monconduit M; Voillat L; Macro M; Berthou C; Dorvaux V; Pignon B; Rio B; Matthes T; Casassus P; Caillot D; Najman N; Grosbois B; Bataille R; Harousseau JL;
Blood; 2002 Feb; 99(3):731-5. PubMed ID: 11806971
[TBL] [Abstract][Full Text] [Related]
7. Autologous stem cell transplantation for multiple myeloma: identification of prognostic factors.
Kumar L; Cyriac SL; Tejomurtula TV; Bahl A; Biswas B; Sahoo RK; Mukherjee A; Sharma O
Clin Lymphoma Myeloma Leuk; 2013 Feb; 13(1):32-41. PubMed ID: 23085487
[TBL] [Abstract][Full Text] [Related]
8. The role of autologous transplantation in patients with multiple myeloma aged 65 years and over.
Sirohi B; Powles R; Treleaven J; Mainwaring P; Kulkarni S; Pandha H; Bhagwati N; Horton C; Singhal S; Mehta J
Bone Marrow Transplant; 2000 Mar; 25(5):533-9. PubMed ID: 10713631
[TBL] [Abstract][Full Text] [Related]
9. Final outcomes of escalated melphalan 280 mg/m
Hari P; Reece DE; Randhawa J; Flomenberg N; Howard DS; Badros AZ; Rapoport AP; Meisenberg BR; Filicko-Ohara J; Phillips GL; Vesole DH
Bone Marrow Transplant; 2019 Feb; 54(2):293-299. PubMed ID: 29907806
[TBL] [Abstract][Full Text] [Related]
10. Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
Rodriguez TE; Hari P; Stiff PJ; Smith SE; Sterrenberg D; Vesole DH
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1391-1396. PubMed ID: 27164062
[TBL] [Abstract][Full Text] [Related]
11. Long-term results in multiple myeloma after high-dose melphalan and autologous transplantation according to response categories in the era of old drugs.
Martino M; Postorino M; Gallo GA; Messina G; Neri S; Piro E; Gentile M; Moscato T; Monteleone R; Fedele R; Mazzone C; Console G; Penna G; Alati C; Vincelli ID; Irrera G; Musolino C; Ronco F; Molica S; Morabito F
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):148-54. PubMed ID: 24417912
[TBL] [Abstract][Full Text] [Related]
12. Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma.
Saad A; Mahindra A; Zhang MJ; Zhong X; Costa LJ; Dispenzieri A; Drobyski WR; Freytes CO; Gale RP; Gasparetto CJ; Holmberg LA; Kamble RT; Krishnan AY; Kyle RA; Marks D; Nishihori T; Pasquini MC; Ramanathan M; Lonial S; Savani BN; Saber W; Sharma M; Sorror ML; Wirk BM; Hari PN
Biol Blood Marrow Transplant; 2014 Mar; 20(3):402-408.e1. PubMed ID: 24342394
[TBL] [Abstract][Full Text] [Related]
13. Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma.
Gertz MA; Lacy MQ; Inwards DJ; Chen MG; Pineda AA; Gastineau DA; Greipp PR; Lust JA; Tefferi A; Witzig TE; Kyle RA; Litzow MR
Bone Marrow Transplant; 1999 Feb; 23(3):221-6. PubMed ID: 10084252
[TBL] [Abstract][Full Text] [Related]
14. Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib.
Aypar E; İzzettin FV; Akı ŞZ; Sancar M; Yeğin ZA; Türköz-Sucak G
J Oncol Pharm Pract; 2018 Jun; 24(4):281-289. PubMed ID: 29284356
[TBL] [Abstract][Full Text] [Related]
15. High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for "De Novo" Multiple Myeloma Patients: A Phase II Study.
Musso M; Messina G; Marcacci G; Crescimanno A; Console G; Donnarumma D; Scalone R; Pinto A; Martino M
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1932-8. PubMed ID: 26099830
[TBL] [Abstract][Full Text] [Related]
16. Impact of the Conditioning Regimen Dose Intensity Before Autologous Stem Cell Transplantation on the Pulmonary Function Test Abnormalities in Patients With Lymphoma and Multiple Myeloma: Single Center Experience.
Bou Akl I; Matar M; Khalil PB; Massoud R; Ghaoui N; Karout L; Zahreddine A; Bazarbachi A; El-Cheikh J
Clin Lymphoma Myeloma Leuk; 2020 Jun; 20(6):371-376.e1. PubMed ID: 32151585
[TBL] [Abstract][Full Text] [Related]
17. Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma.
Poenisch W; Plötze M; Holzvogt B; Andrea M; Schliwa T; Zehrfeld T; Hammerschmidt D; Schwarz M; Edelmann T; Becker C; Hoffmann FA; Schwarzer A; Kreibich U; Gutsche K; Reifenrath K; Schwarzbach H; Heyn S; Franke GN; Jentzsch M; Leiblein S; Schwind S; Lange T; Vucinic V; AlAli HK; Niederwieser D
J Cancer Res Clin Oncol; 2015 Nov; 141(11):2013-22. PubMed ID: 25976868
[TBL] [Abstract][Full Text] [Related]
18. Melphalan versus melphalan plus busulphan in conditioning to autologous stem cell transplantation for low-risk multiple myeloma.
Ria R; Falzetti F; Ballanti S; Minelli O; Di Ianni M; Cimminiello M; Vacca A; Dammacco F; Martelli MF; Tabilio A
Hematol J; 2004; 5(2):118-22. PubMed ID: 15048061
[TBL] [Abstract][Full Text] [Related]
19. Transplantation in patients with multiple myeloma: a multicenter comparative analysis of peripheral blood stem cell and allogeneic transplant.
Varterasian M; Janakiraman N; Karanes C; Abella E; Uberti J; Dragovic J; Raman SB; al-Katib A; Du W; Silver SM; Adams PT; Sensenbrenner L; Ratanatharathorn V
Am J Clin Oncol; 1997 Oct; 20(5):462-6. PubMed ID: 9345328
[TBL] [Abstract][Full Text] [Related]
20. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
Child JA; Morgan GJ; Davies FE; Owen RG; Bell SE; Hawkins K; Brown J; Drayson MT; Selby PJ;
N Engl J Med; 2003 May; 348(19):1875-83. PubMed ID: 12736280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]